Beth Israel Deaconess Medical Center, Inc.

University of Connecticut

Whitehead Institute for Biomedical Research

Beth Israel Hospital Assoc.

The State University of New York

Seth L Alper

Gerald R Fink

Roberto A Gaxiola

Carlo Brugnara

Frederick Sachs

Thomas Suchyna

Philip Gottlieb

David H Vandorpe

Chang Xu

The present invention provides methods and compositions for inhibiting calcium permeable cation conductance of red blood cells from individuals afflicted with sickle cell anemia. The method comprises exposing the cells to the peptide GsMTx4 and/or variants thereof.

[object Object]

The present invention relates to a transgenic plant which is tolerant to a salt, comprising one or more plant cells transformed with exogenous nucleic acid which alters expression of vacuolar pyrophosphatase in the plant. The present invention also relates to a transgenic plant with increased Pi uptake, comprising one or more plant cells transformed with exogenous nucleic acid which alters expression of vacuolar pyrophosphatase in the plant. Also encompassed by the present invention are transgenic progeny and seeds of the transgenic plants described herein. Progeny transgenic plant grown from seed are also described.

Vacuolar pyrophosphatases and uses in plants

Methods are provided for imparting desirable phenotypic traits to transgenic plants, among them being increased tolerance to external stresses such as drought, freezing temperatures, high salt conditions, and the like. In addition, the present invention is directed toward methods for increasing the yield of seeds from plants by using the pollen from a transgenic plant transformed to overexpress a vacuolar proton-pumping pyrophosphatase to fertilize plants, and to the pollen of transgenic plants itself.

Transgenic pollen expressing exogenous plant vacuolar pyrophosphatase and methods for increasing seed production in plants

The present invention relates to a transgenic plant, comprising one or more plant cells transformed with exogenous nucleic acid which increases expression of vacuolar pyrophosphatase in the plant. Also encompassed by the present invention are transgenic progeny and seeds of the transgenic plants described herein. Progeny transgenic plants grown from seed are also described. Plant cells (e.g., root cells, stem cells, leaf cells) comprising exogenous nucleic acid which increases expression of vacuolar pyrophosphatase in the plant cells are also the subject of the present invention. Also encompassed by the present invention are methods of making a transgenic plant described herein. The present invention also relates to a method of increasing the yield of a plant, a method of making a plant which is larger than its corresponding wild type plant, and a method of producing a transgenic plant with increased salt tolerance.

Plant cells and plants overexpressing vacuolar proton pyrophosphatases

Transgenic plants are described which are engineered to overexpress vacuolar H-PPase. Plants such as tobacco and petunia transformed withAVP-1 are shown to have increased meristematic activity resulting in larger leaves, stem, flower, fruit, root structures, increased salt tolerance, enhanced drought and freeze tolerance. Methods of making such plants are also described.

Transgenic plants overexpressing a plant vacuolar pyrophosphatase

Transgenic plants overexpressing a plant vacuolar H + -ATPase

The present invention provides a chemical class of active compounds to be used as efficacious drugs in the treatment of sickle cell disease. The active compounds include imidazole derivatives, nitroimidazole derivatives, and triazole derivatives. These compounds are to be administered by any preferred route of administration including oral, intramuscular, intravenous, and any other parenteral route. If desired, these drugs may also be administered transmucosally, or subcutaneously, or using a dermal patch on the skin. In addition, the methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in emergency, acute crisis clinical situations.

Growing community of inventors

Boston, MA, United States of America

Seth L Alper